Given the growing interest in respiratory treatments and AstraZeneca’s market position amidst ongoing scrutiny, I see potential for a short-term uptick in AZN shares. With increased demand for respiratory drugs, this presents a timely opportunity for investment before market adjustments occur.

Given AstraZeneca's strong pipeline and portfolio in the oncology and targeted therapeutics markets, combined with the expected growth in the cancer and therapeutics sectors, I'm expecting significant short-term gains. Investor sentiment is likely to be positive as these markets expand and healthcare awareness increases.